全文获取类型
| 收费全文 | 1274058篇 |
| 免费 | 84004篇 |
| 国内免费 | 2874篇 |
专业分类
| 耳鼻咽喉 | 15503篇 |
| 儿科学 | 43664篇 |
| 妇产科学 | 33861篇 |
| 基础医学 | 176933篇 |
| 口腔科学 | 31228篇 |
| 临床医学 | 111754篇 |
| 内科学 | 245518篇 |
| 皮肤病学 | 24652篇 |
| 神经病学 | 104050篇 |
| 特种医学 | 50743篇 |
| 外国民族医学 | 308篇 |
| 外科学 | 196072篇 |
| 综合类 | 27713篇 |
| 现状与发展 | 1篇 |
| 一般理论 | 455篇 |
| 预防医学 | 103394篇 |
| 眼科学 | 27827篇 |
| 药学 | 87810篇 |
| 3篇 | |
| 中国医学 | 2787篇 |
| 肿瘤学 | 76660篇 |
出版年
| 2019年 | 8702篇 |
| 2018年 | 34769篇 |
| 2017年 | 27473篇 |
| 2016年 | 31786篇 |
| 2015年 | 13203篇 |
| 2014年 | 17609篇 |
| 2013年 | 26655篇 |
| 2012年 | 41269篇 |
| 2011年 | 57989篇 |
| 2010年 | 40507篇 |
| 2009年 | 32305篇 |
| 2008年 | 55111篇 |
| 2007年 | 60814篇 |
| 2006年 | 37215篇 |
| 2005年 | 38349篇 |
| 2004年 | 38991篇 |
| 2003年 | 39256篇 |
| 2002年 | 36042篇 |
| 2001年 | 48109篇 |
| 2000年 | 49271篇 |
| 1999年 | 41263篇 |
| 1998年 | 12602篇 |
| 1997年 | 11475篇 |
| 1996年 | 11173篇 |
| 1995年 | 10803篇 |
| 1994年 | 10052篇 |
| 1993年 | 9318篇 |
| 1992年 | 32897篇 |
| 1991年 | 32120篇 |
| 1990年 | 31601篇 |
| 1989年 | 30447篇 |
| 1988年 | 27682篇 |
| 1987年 | 27855篇 |
| 1986年 | 25958篇 |
| 1985年 | 25163篇 |
| 1984年 | 19122篇 |
| 1983年 | 16258篇 |
| 1982年 | 10281篇 |
| 1981年 | 9221篇 |
| 1979年 | 17355篇 |
| 1978年 | 12765篇 |
| 1977年 | 10873篇 |
| 1976年 | 10280篇 |
| 1975年 | 10590篇 |
| 1974年 | 12670篇 |
| 1973年 | 12163篇 |
| 1972年 | 11130篇 |
| 1971年 | 10281篇 |
| 1970年 | 9576篇 |
| 1969年 | 8877篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
11.
Thomas Felix John B. Jordan Catherine Akers Bina Patel Daniela Drago 《Expert opinion on drug safety》2019,18(3):231-240
Introduction: Pharmacovigilance is essential to monitoring the safety profiles of authorized medicines. Compared with small-molecule drugs, biological drugs are more complex, more susceptible to structural variability due to manufacturing processes, and have the potential to induce immune-related reactions, underscoring the importance of safety monitoring for these products. Although highly similar to reference products, biosimilars are not expected to be structurally identical. For these reasons, proper reporting of potential adverse drug reactions (ADRs) using distinguishable names and batch numbers is essential for accurate tracing of all biological drugs. To address the need for robust pharmacovigilance, the European Parliament and Council of the European Union provided legislation regarding pharmacovigilance of biologics in 2010.
Areas covered: This narrative review examines the current state of pharmacovigilance for biologics in the European Union (EU) and discusses relevant information on pharmacovigilance of biosimilars, the current EU pharmacovigilance system, and areas that could be improved.
Expert opinion: Although steps have been taken to improve pharmacovigilance of biologics in the EU, several enhancements can still be made, including additional training for healthcare professionals on ADR reporting, the use of 2D barcodes that enhance traceability, and an open discussion of potentially missed opportunities in the pharmacovigilance of biosimilars. 相似文献
12.
13.
14.
15.
16.
17.
18.
19.
Alexandra B. Morshed Rachel G. Tabak Cynthia D. Schwarz Debra Haire-Joshu 《Journal of nutrition education and behavior》2019,51(2):237-244
Objective
To examine whether a healthy weight intervention embedded in the Parents as Teachers (PAT) home visiting program, which was previously found to improve mothers’ body mass index (BMI) and obesity-related behaviors, changed the BMI of preschool children or maternal feeding practices.Methods
This stratified randomized trial included preschool-aged children at risk for overweight whose mothers were overweight or had obesity (n?=?179). The Healthy Eating and Active Living Taught at Home (HEALTH) intervention was based on the Diabetes Prevention Program. Differences were examined using repeated-measures mixed-ANOVA models.Results
Compared with PAT usual care, the HEALTH intervention had no effect on children's BMI or maternal feeding practices. However, combined analyses showed that children's BMI percentile decreased (P??=?.007), BMI z-scores were maintained (P??=?.19), and 3 of 8 feeding practices improved over time (P < .05).Conclusions and Implications
Additional research is needed to assess the effectiveness of PAT to prevent preschool-age obesity using rigorous designs (eg, group-randomized trials) and to identify its active components. HEALTH is ready to be scaled up to prevent maternal weight gain through embedding within the national PAT program. 相似文献20.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349